| Gene symbol | CD22 | Synonyms | SIGLEC-2, SIGLEC2 | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19q13.12 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | CD22 molecule | ||||
| GTO ID | GTC3875 |
| Trial ID | NCT06408194 |
| Disease | Leukemia | Acute Lymphoblastic Leukemia |
| Altered gene | CD22 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD22 CAR-T cells |
| Co-treatment | Tisagenlecleucel |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | Phase I/Ib Clinical Trial of Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells Following Commercial CD19 CAR T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies |
| Year | 2024 |
| Country | United States |
| Company sponsor | Stanford University |
| Other ID(s) | IRB-74214|NCI-2024-04331 |
| Cohort 1 | |||||||||||
|
|||||||||||